Claims for Patent: 10,206,992

Summary for Patent: 10,206,992

Title:	MDR E. coli specific antibody
Abstract:	The subject relates to an isolated antibody that specifically binds to O25b antigen of multi drug resistant (MDR) E. coli strains, its medical and diagnostic use, method of producing the antibody, including an isolated nucleotide sequence, plasmids and host cells as used in the production of the antibody; and further an isolated epitope recognized the specific antibody.
Inventor(s):	Nagy; Eszter (Vienna, AT), Nagy; Gabor (Sopron, HU), Szijarto; Valeria (Vienna, AT), Magyarics; Zoltan (Vienna, AT), Mirkina; Irina (Vienna, AT), Guachalla; Luis (Vienna, AT), Badarau; Adriana (Vienna, AT), Zauner; Gerhild (Vienna, AT), Lukasiewicz; Jolanta (Wroclaw, PL)
Assignee:	ARSANIS BIOSCIENCES GMBH (Vienna, AT)
Application Number:	15/373,528
Patent Claims:	1. A composition comprising an O25b antigen having the structure: ##STR00001## and an adjuvant, a liposome or a cationic peptide. 2. The composition of claim 1, wherein the 025b antigen is recognized by an antibody which comprises a) the variable region of the antibody light chain produced by the host cell deposited under DSM 26763; and b) the variable region of the antibody heavy chain produced by the host cell deposited under DSM 26762; or an antibody which comprises a) the variable region of the antibody light chain produced by the host cell deposited under DSM 28171; and b) the variable region of the antibody heavy chain produced by the host cell deposited under DSM 28172. 3. The composition of claim 1, further comprising a solvent, dispersion media, coating, antibacterial agent, antifungal agent, isotonic agent, absorption delaying agent or a combination thereof. 4. The composition of claim 1, further comprising sterile water, saline, phosphate buffered saline, dextrose, glycerol, ethanol or a combination thereof. 5. The composition of claim 1, wherein the adjuvant is selected from the group consisting of aluminum phosphate, aluminum hydroxide, CpG oligonucleotide, and combinations thereof. 6. The composition of claim 1, which elicits an immune response when administered in an effective amount to a subject. 7. The composition of claim 6, wherein the immune response is a cellular and/or antibody-mediated immune response. 8. An immunogenic composition comprising an effective amount of an O25b antigen having the structure: ##STR00002## and an adjuvant. 9. The immunogenic composition of claim 8, wherein the adjuvant is selected from the group consisting of aluminum phosphate, aluminum hydroxide, CpG oligonucleotide, and combinations thereof. 10. The immunogenic composition of claim 8 wherein the adjuvant is a carrier that elicits an immune response when administered in conjunction with an effective amount of the O25b antigen to a subject. 11. The immunogenic composition of claim 10, wherein the immune response is a cellular and/or antibody-mediated immune response. 12. The immunogenic composition of claim 10, wherein the effective amount is administered as a first dose followed by one or more booster dose(s). 13. The immunogenic composition of claim 12, wherein 3 doses are administered. 14. A vaccine formulation comprising an effective amount of an O25b antigen having the structure: ##STR00003## and an adjuvant, wherein the vaccine formulation is formulated for parental administration. 15. The vaccine formulation of claim 14, wherein the adjuvant is selected from the group consisting of aluminum phosphate, aluminum hydroxide, CpG oligonucleotide, and combinations thereof. 16. The vaccine formulation of claim 14, wherein the parental administration is subcutaneous, intravenous or intramuscular. 17. The vaccine formulation of claim 14, wherein the formulation is a sterile solution, emulsion or suspension. 18. The vaccine formulation of claim 14, comprising an excipient, carrier and/or stabilizer. 19. The vaccine formulation of claim 18, wherein the excipient is selected from the group consisting of a suspending agent, solubilizer, surfactant, preservative, chelating agent, and combinations thereof. 20. The vaccine formulation of claim 14 which elicits an immune response when administered in an effective amount to a subject. 21. The vaccine formulation of claim 20, wherein the immune response is a cellular and/or antibody-mediated immune response. 22. The vaccine formulation of claim 20, wherein the effective amount is administered as a first dose followed by one or more booster dose(s). 23. The vaccine formulation of claim 22, wherein 3 doses are administered.

Details for Patent 10,206,992

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006		2033-01-17